News Releases

Date Title and Summary View
May 29, 2018
– KVD900 Data Accepted for Late Breaking Poster Session –

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 29, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule...
Additional Formats
May 16, 2018
– A Global Awareness Day for a Rare Life-Threatening Condition –

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 16, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small...
Additional Formats
May 2, 2018
– Oral Plasma Kallikrein Inhibitor Blocks VEGF-induced Retinal Vascular Hyperpermeability –

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small...
Additional Formats
April 18, 2018
– Oral Plasma Kallikrein Inhibitor Data in a Preclinical Model of Retinal Edema to be Presented –

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 18, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization...
Additional Formats
March 16, 2018
– Enrollment Ongoing for a Phase 2 Clinical Trial of KVD001 in Diabetic Macular Edema (“DME”) and a Phase 1 Clinical Trial for the Second Candidate in the Oral Hereditary Angioedema (“HAE ” ) Portfolio –

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 16, 2018-- KalVista Pharmaceuticals, Inc....
Additional Formats
March 5, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at...
Additional Formats
January 5, 2018
– Data Expected for Phase 2 Clinical Trial of KVD001 in Diabetic Macular Edema Patients in the Second Half of 2019 –

– Second Oral Hereditary Angioedema Candidate Begins Phase 1 Clinical Trial –

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 5, 2018-- KalVista Pharmaceuticals, Inc....
Additional Formats
Displaying 11 - 17 of 17